Comparative Pharmacology
Head-to-head clinical analysis: MECAMYLAMINE HYDROCHLORIDE versus RAUDIXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MECAMYLAMINE HYDROCHLORIDE versus RAUDIXIN.
MECAMYLAMINE HYDROCHLORIDE vs RAUDIXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mecamylamine is a noncompetitive antagonist of nicotinic acetylcholine receptors (nAChRs) with highest affinity for α3β4 and α4β2 subtypes. It blocks ganglionic transmission in both sympathetic and parasympathetic ganglia, leading to decreased catecholamine release and antihypertensive effects.
Raudixin (reserpine) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral neuronal storage granules by inhibiting vesicular monoamine transporter (VMAT). This leads to prolonged sympathetic blockade and reduced blood pressure.
Initially 2.5 mg orally twice daily, gradually increased by 2.5 mg increments at intervals of 2 or more days; usual maintenance dose 25 mg/day in divided doses.
Usual adult dose: 400–1600 mg orally per day in divided doses; maximum 2400 mg/day; for severe agitation: 50–100 mg intramuscularly every 4–6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 12-24 hours; clinically, this allows once or twice daily dosing but requires dose adjustment in renal impairment.
Terminal elimination half-life 50-100 hours; clinical context: once-daily dosing achieves steady state in 1-2 weeks.
Renal: 50-70% unchanged; biliary/fecal: minimal (less than 5%)
Primarily renal (80-90% as unchanged drug), minor biliary/fecal (10-20%).
Category C
Category C
Antihypertensive
Antihypertensive